These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
128 related items for PubMed ID: 12701940
1. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. Int J Technol Assess Health Care; 2003; 19(1):71-9. PubMed ID: 12701940 [Abstract] [Full Text] [Related]
2. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, Bush A. Thorax; 2002 Oct; 57(10):841-6. PubMed ID: 12324668 [Abstract] [Full Text] [Related]
3. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, Thompson S, Bush A, Wallis C. Lancet; 2001 Oct 20; 358(9290):1316-21. PubMed ID: 11684212 [Abstract] [Full Text] [Related]
4. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Suri R, Metcalfe C, Wallis C, Bush A. Pediatr Pulmonol; 2004 Apr 20; 37(4):305-10. PubMed ID: 15022126 [Abstract] [Full Text] [Related]
5. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, Grieve R, Metcalfe C, Lees B. Health Technol Assess; 2002 Apr 20; 6(34):iii, 1-60. PubMed ID: 12583821 [No Abstract] [Full Text] [Related]
6. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Am J Respir Crit Care Med; 2002 Aug 01; 166(3):352-5. PubMed ID: 12153969 [Abstract] [Full Text] [Related]
7. Recombinant human deoxyribonuclease for cystic fibrosis. Jones AP, Wallis CE. Cochrane Database Syst Rev; 2003 Aug 01; (3):CD001127. PubMed ID: 12917899 [Abstract] [Full Text] [Related]
8. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV. Am Rev Respir Dis; 1993 Jul 01; 148(1):145-51. PubMed ID: 8317790 [Abstract] [Full Text] [Related]
9. rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. Christopher F, Chase D, Stein K, Milne R. J Clin Pharm Ther; 1999 Dec 01; 24(6):415-26. PubMed ID: 10651974 [Abstract] [Full Text] [Related]
10. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Minasian C, Wallis C, Metcalfe C, Bush A. Thorax; 2010 Jan 01; 65(1):51-6. PubMed ID: 19996349 [Abstract] [Full Text] [Related]
11. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis. Henry RL, Gibson PG, Carty K, Cai Y, Francis JL. Pediatr Pulmonol; 1998 Aug 01; 26(2):97-100. PubMed ID: 9727759 [Abstract] [Full Text] [Related]
12. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis]. von der Schulenburg JM, Greiner W, von der Hardt H. Med Klin (Munich); 1995 Apr 15; 90(4):220-4. PubMed ID: 7776934 [Abstract] [Full Text] [Related]
13. The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. Suri R. BioDrugs; 2005 Apr 15; 19(3):135-44. PubMed ID: 15984899 [Abstract] [Full Text] [Related]
14. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni C, Merot JL, Rossi F, vd Schulenburg JG, Souêtre E. Int J Technol Assess Health Care; 1996 Apr 15; 12(1):52-61. PubMed ID: 8690562 [Abstract] [Full Text] [Related]
15. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Am J Respir Crit Care Med; 1996 Feb 15; 153(2):752-60. PubMed ID: 8564129 [Abstract] [Full Text] [Related]
16. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Am J Respir Crit Care Med; 1997 Jul 15; 156(1):173-7. PubMed ID: 9230743 [Abstract] [Full Text] [Related]
17. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Shak S. Chest; 1995 Feb 15; 107(2 Suppl):65S-70S. PubMed ID: 7842816 [Abstract] [Full Text] [Related]
18. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ. Ann Pharmacother; 1995 May 15; 29(5):459-64. PubMed ID: 7655127 [Abstract] [Full Text] [Related]
19. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. N Engl J Med; 1994 Sep 08; 331(10):637-42. PubMed ID: 7503821 [Abstract] [Full Text] [Related]
20. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE. Eur Respir J; 1995 Jun 08; 8(6):954-8. PubMed ID: 7589382 [Abstract] [Full Text] [Related] Page: [Next] [New Search]